Physician profile
Jack Facundus
NPI 1376092809
$4,672.32
in general payments reported to CMS, 2019-2025
25 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $1,054 · 2023: $564 · 2024: $1,265 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.47 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $367.20 | 2023-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $353.46 | 2024-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $325.68 | 2021-2025 | Livdelzi |
| Teva Pharmaceuticals USA, INC. | $302.39 | 2024-2025 | Austedo Xr, Uzedy |
| Grifols USA, LLC | $251.63 | 2022-2024 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $249.27 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $239.10 | 2024-2025 | Cobenfy |
| Paratek Pharmaceuticals, INC. | $226.49 | 2022-2023 | Nuzyra |
| Biogen, INC. | $194.78 | 2022-2024 | |
| Genzyme Corporation | $190.66 | 2022-2025 | |
| Medtronic, INC. | $146.44 | 2025 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $140.48 | 2024 | Invega Sustenna |
| Bard Access Systems, INC. | $134.03 | 2021 | |
| Vanda Pharmaceuticals INC. | $124.97 | 2024 | Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $121.86 | 2023 | Auvelity |
| Amgen INC. | $117.12 | 2025 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.03 | 2021 | |
| Genentech USA, INC. | $113.71 | 2021 | |
| Horizon Therapeutics Plc | $101.20 | 2022 | |
| Abiomed | $95.55 | 2025 | |
| Glaxosmithkline, LLC. | $92.05 | 2024 | Arexvy |
| Esperion Therapeutics, INC. | $90.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.40 | 2022 | |
| Grt US Holding, INC. | $88.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Facundus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.